Organogenesis Holdings Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $179.000M-$215.000M vs $282.850M Est
Benzinga Newsdesk 3 months ago
NewsGuidance
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $270.000 million-$310.000 million to $179.000 million-$215.000 million vs $282.850 million estimate.
Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $270.000 million-$310.000 million to $179.000 million-$215.000 million vs $282.850 million estimate.